A Prospective, Multi-Center Clinical Utility Study Demonstrates That the 40-Gene Expression Profile (40-GEP) Test Impacts Clinical Management for Medicare-Eligible Patients With High-Risk Cutaneous Squamous Cell Carcinoma (cSCC). J of Skin 2022, 6 (6), 482-496. https://doi.org/10.25251/skin.6.6.5.